Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A liquid pharmaceutical composition comprising (i) ~~cetirizine,~~ levocetirizine~~, efletirizine,~~ or a pharmaceutically acceptable salt of ~~cetirizine~~, levocetirizine~~, or efletirizine~~, and (ii) at least one preservative, wherein the preservative is ~~(a) a parahydroxybenzoate ester that is present in an amount of more than 0 and less than 1.5 mg/ml of the composition, or (b) a preservative other than a parahydroxybenzoate ester that is present in an amount having the same bactericidal effect on the composition as a parahydroxybenzoate ester of concentration of more than 0 and less than 1.5 mg/ml.~~ a mixture of methyl parahydroxybenzoate and propyl parahydroxybenzoate in a ratio of 9/1 expressed in weight, said mixture being present in an amount of more than 0 and less than 1.5 mg/ml of the composition.

2. (Previously presented) The liquid pharmaceutical composition according to claim 1, wherein the composition is aqueous.

3. (Canceled)

4. (Canceled)

5. (Currently amended) The liquid pharmaceutical composition according to claim [[4]] 1, wherein the amount of p-hydroxybenzoate esters is in the range of 0.0001 and [[1.4]] 1.5 mg/ml of the composition.

6. (Withdrawn) The liquid pharmaceutical composition according to claim 1, wherein the pharmaceutical composition contains an amount of thimerosal in the range of 0.0001 and 0.05 mg/ml of the composition.

7. (Withdrawn) The liquid pharmaceutical composition according to claim 1, wherein the pharmaceutical composition contains an amount of chlorhexidine acetate in the range of 0.0001 and 0.05 mg/ml of the composition.

8. (Withdrawn) The liquid pharmaceutical composition according to claim 1, wherein the pharmaceutical composition contains an amount of benzylalcohol in the range of 0.0001 and 10 mg/ml of the composition.

9. (Withdrawn) The liquid pharmaceutical composition according to claim 1, wherein the pharmaceutical composition contains an amount of benzalkonium chloride in the range of 0.0001 and 0.05 mg/ml of the composition.

10. (Withdrawn) The liquid pharmaceutical composition according to claim 1, wherein the active substance is cetirizine.

11. (Canceled)

12. (Previously presented) The liquid pharmaceutical composition according to claim 1, wherein the composition is in the form of oral solutions, nasal drops, eye drops or ear drops.

13. (Canceled)

14. (Previously Presented) The liquid pharmaceutical composition according to claim 13, wherein the pharmaceutically acceptable salt of levocetirizine is a hydrochloride salt.

15. (Previously Presented) The liquid pharmaceutical composition according to claim 14, wherein the hydrochloride salt of levocetirizine is present in amount of 0.5 mg/ml and the mixture of methyl p-hydroxybenzoate and propyl p-hydroxybenzoate is present in amount of 0.75 mg/ml.

16. (Canceled)

17. (Previously presented) The liquid pharmaceutical composition according to claim 1, which composition comprises levocetirizine or a pharmaceutically acceptable salt that is at least 95% by weight of the levorotatory enantiomer of cetirizine.

18. (Withdrawn) A method of making a liquid pharmaceutical composition according to claim 1 comprising combining,

a) cetirizine, levocetirizine, efletirizine, or a pharmaceutically acceptable salt of cetirizine, levocetirizine, or efletirizine, and

b) parahydroxybenzoate ester in an amount of more than 0 and less than 1.5 mg/ml of the composition.

19. (Withdrawn) The method according to claim 18, comprising mixing levocetirizine or a pharmaceutically acceptable salt thereof with a mixture of methyl p-hydroxybenzoate and propyl p-hydroxybenzoate.

20. (Withdrawn) The method according to claim 19, comprising mixing a pharmaceutically acceptable salt of levocetirizine with a mixture of methyl p-hydroxybenzoate and propyl p-hydroxybenzoate, wherein the methyl p-hydroxybenzoate and propyl p-hydroxybenzoate are present in a ratio of 9:1.

21. (Withdrawn) The method according to claim 20, wherein the pharmaceutically acceptable salt of levocetirizine is a hydrochloride salt.

22. (Withdrawn) In a method of treating a patient with cetirizine, levocetirizine, efletirizine, or a pharmaceutically acceptable salt of cetirizine, levocetirizine, or efletirizine, the improvement comprising administering a liquid composition according to claim 1.

23. (Withdrawn) The method according to claim 23, wherein the liquid composition comprises levocetirizine or a pharmaceutically acceptable salt thereof and a mixture of methyl p-hydroxybenzoate and propyl p-hydroxybenzoate.

24. (Withdrawn) The method according to claim 23, wherein the pharmaceutically acceptable salt of levocetirizine is a hydrochloride salt.

25. (Withdrawn) The method according to claim 24, wherein the hydrochloride salt of levocetirizine is present in amount of 0.5 mg/ml and the mixture of methyl p-hydroxybenzoate and propyl p-hydroxybenzoate is present in amount of 0.75 mg/ml.

26. (Withdrawn) The method according to claim 25, wherein the methyl p-hydroxybenzoate and propyl p-hydroxybenzoate are present in a ratio of 9:1 by weight.